Results 181 to 187 of about 10,491 (187)

Risk factors for raltegravir resistance development in clinical practice

Journal of Antimicrobial Chemotherapy, 2012
Isabelle Malet, Laurence Morand-Joubert, Philippe Flandre   +2 more
exaly  

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

Journal of Clinical Pharmacology, 2008
T C Marbury, K Gottesdiener
exaly  

Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir

Clinical Infectious Diseases, 2017
Mark G Thomas, Christopher Hopkins, Eamon Duffy   +2 more
exaly  

Raltegravir: The first HIV integrase inhibitor

Clinical Therapeutics, 2008
Jennifer Cocohoba
exaly  

Treatment of HIV infection with raltegravir

Expert Opinion on Pharmacotherapy, 2009
Roy T Steigbigel
exaly  

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

Journal of Antimicrobial Chemotherapy, 2017
Ana Trevino, TERESA Cabezas, Vincent Soriano   +2 more
exaly  

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Lancet, The, 2009
Jeffrey L Lennox, Edwin Dejesus, Adriano Lazzarin   +2 more
exaly